HealthOrbit, Inc.

New Drug for Advanced Prostate Cancer Shows Promise

OHSU Knight Cancer Institute is one of four centers worldwide to evaluate the new compound

A new drug called MDV3100 has shown significant promise in lowering the prostate specific antigen (PSA) levels ‑ a marker for tumor growth ‑ in men with advanced prostate cancer who have no other option for cure.

The drug has also been shown to shrink prostate cancer lesions seen on imaging studies. The Oregon Health & Science University Knight Cancer Institute is one of just four centers worldwide to enroll participants in a Phase I/II clinical trial that contributed to this discovery.

The findings are described in a new study published in this week’s Science Express, the online version of the journal Science.

“We are encouraged by the benefits participants are experiencing from this research,” said Tomasz Beer, M.D., OHSU principal investigator, director of the Prostate Cancer Research Program and deputy director of the OHSU Knight Cancer Institute. “This clinical trial is yet another example of how the OHSU Knight Cancer Institute is able to consistently bring the most exciting and promising new drugs and treatment options to Oregonians. Patients no longer need to travel anywhere else in the world to receive the latest, most state-of-the-art cancer care.”

Full details of this news is only available to our members.
If you are a member, please log in now.